Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Gilead Sciences (NASDAQ:GILD), a biopharmaceutical powerhouse known for its dominant HIV franchise, finds itself at a critical juncture as it navigates challenges in oncology while seeking to ...

Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and ...

Gilead Sciences (NASDAQ:GILD), a biopharmaceutical powerhouse known for its dominant HIV franchise, finds itself at a critical juncture as it navigates challenges in oncology while seeking to ...